HAL will be down for maintenance from Friday, June 10 at 4pm through Monday, June 13 at 9am. More information
Skip to Main content Skip to Navigation
Master Thesis

Maintien thérapeutique des inhibiteurs de JAK et des bDMARDs dans la polyarthrite rhumatoïde

Abstract : Objectives: the continuation rate of a drug is an indirect measure of effectiveness and tolerance. The aim of this study was to assess the therapeutic maintenance in real-life of biologic drug modifying rheumatic diseases (bDMARDs) and JAK inhibitors (JAKi) in rheumatoid arthritis (RA) over an 18-month period and to analyze factors predictive of treatment continuation as well as reasons for discontinuation. Methods: This is a retrospective analysis of the medical records of RA patients followed at Bordeaux University Hospital who received a new prescription for a JAKi or a bDMARD between November 1, 2017 and October 10, 2018. Clinical and biological data were collected at baseline and up to a 18-month follow-up. Survival curves were constructed using the Kaplan-Meier method and comparison made by logrank testing. Factors associated with maintenance at 12 and 18 months were assessed by univariate and multivariate analyses. Results: among the 129 patients included, 47 were prescribed a JAKi, 43 a TNF inhibitor (TNFi) and 39 another bDMARD (abatacept, rituximab, anti IL6). At 18 months, the global therapeutic maintenance rate was 39% (45% for JAKi, 37% for TNFi and 33% for other bDMARDs). There was no significant difference in the crude overall drug retention between treatments (p = 0,26). Presence of corticosteroids at initiation was the only predictive factor associated with maintenance in both univariate and multivariate analysis by showing a higher discontinuation at 18 months (p = 0.05). However concomitant csDMARDs therapy showed no association with continuation (p = 0,87). The main causes of discontinuation were global lack of efficacy at 51% and occurrence of adverse events (AE) at 38%. Conclusion: This observational study has shown a similar drug retention between JAKi and other bDMARDs.
Complete list of metadata

Contributor : Médecine Ub Connect in order to contact the contributor
Submitted on : Monday, October 4, 2021 - 10:06:39 AM
Last modification on : Wednesday, November 3, 2021 - 5:23:47 AM
Long-term archiving on: : Wednesday, January 5, 2022 - 6:14:09 PM


Files produced by the author(s)


  • HAL Id : dumas-03363643, version 1



Camille Bie. Maintien thérapeutique des inhibiteurs de JAK et des bDMARDs dans la polyarthrite rhumatoïde. Sciences du Vivant [q-bio]. 2020. ⟨dumas-03363643⟩



Record views


Files downloads